Introduction:
Leading pharma facility inspection has been classified as “Official Action Indicated” by the US FDA. The company is addressing observations, implementing enhancements, and collaborating with experts to ensure compliance and maintain high-quality production standards.
Also Read: Green energy stock jumps 4% after it receives order for solar PV plant from Coal India
Share price movement of Granules India:
On December 3, 2024, Granules India Ltd opened at ₹597.50, down 10.12% from its previous close of ₹594.65. The stock reached a high of ₹627.45 and a low of ₹528.70. The stock closed at ₹534.45, reflecting a significant drop. The company’s market cap stood at ₹12,953.40 crore.
Gagillapur Facility Under OAI Classification:
Granules India reported that the US FDA has classified its Gagillapur facility inspection as “Official Action Indicated” (OAI). This follows a prior inspection that resulted in Form 483 with six observations highlighting areas for improvement.
In response, the company has addressed all observations and initiated a thorough facility evaluation. Collaborating with external subject matter experts, it is implementing enhancements to align with US FDA compliance standards and bolster operational efficiency.
Granules India is actively engaging with the US FDA and remains confident of resolving the issues swiftly. The company reaffirms its commitment to regulatory compliance and delivering high-quality pharmaceutical product.
Recent news on Granules India:
As of 7 Nov 2024, Granules India reported a decline in Q2 results, with an 18.74% revenue drop and a 4.78% profit decrease year-over-year. Compared to the previous quarter, revenue fell by 18.07%, and profit dropped by 27.79%.
Stock performance of Granules India for Period of 1 week, 6 months and 1 year:
Granules India has shown strong performance over the long term, with a 52% return over the past year and a 27.1% increase over the last 6 months. However, the stock saw a slight dip of -0.04% over the past week.
Also Read: IT stock hits 5% upper circuit after it partners with central bank of India
Shareholding pattern of Granules India:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 38.90% | 38.90% | 42.00% |
| FII | 19.50% | 20.40% | 19.60% |
| DII | 14.90% | 14.10% | 10.70% |
| Public | 26.80% | 26.60% | 27.80% |
About Granules India:
Granules India Ltd (NSE: GRANULES) specializes in manufacturing and selling Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages. The company plays a key role in the pharmaceutical industry with a focus on quality and innovation.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
